Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway

Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve CLL. Besides directly inhibiting BTK, ibrutinib possesses immunomodulatory properties through targeting multiple signaling pathways. Understanding how th...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Leukemia
Huvudupphovsmän: Kondo, Kayo, Shaim, Hila, Thompson, Philip A., Burger, Jan A., Keating, Michael, Estrov, Zeev, Harris, David, Kim, Ekaterina, Ferrajoli, Alessandra, Daher, May, Basar, Rafet, Muftuoglu, Muharrem, Imahashi, Nobuhiko, Alsuliman, Abdullah, Wierda, William, Jain, Nitin, Liu, Enli, Shpall, Elizabeth J., Rezvani, Katayoun
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128536/
https://ncbi.nlm.nih.gov/pubmed/28972595
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.304
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk